Abstract | INTRODUCTION: In 2008, the Food and Drugs Administration required manufacturers of TNFalpha antagonists to strengthen their warnings about the risk of serious fungal infections in patients with rheumatoid arthritis (RA). Sinus aspergilloma occurs occasionally in RA patients and can progress to invasive Aspergillus disease. The purpose of this study was to describe symptomatic sinus aspergilloma in RA patients treated with TNFalpha antagonists. METHODS: Retrospective descriptive study of symptomatic cases of sinus aspergilloma in patients with RA followed in three French university hospitals. A systematic literature review was performed. RESULTS: CONCLUSIONS: Otorhinolaryngological symptoms must be evaluated before starting or switching TNFalpha antagonists. Routine computed tomography of the sinuses before starting or switching TNFalpha antagonists may deserve consideration.
|
Authors | Ariane Leboime, Jean-Marie Berthelot, Yannick Allanore, Lama Khalil-Kallouche, Philippe Herman, Philippe Orcel, Frédéric Lioté |
Journal | Arthritis research & therapy
(Arthritis Res Ther)
Vol. 11
Issue 6
Pg. R164
( 2009)
ISSN: 1478-6362 [Electronic] England |
PMID | 19886992
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antirheumatic Agents
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Tumor Necrosis Factor-alpha
- Infliximab
- Etanercept
|
Topics |
- Aged
- Antibodies, Monoclonal
(therapeutic use)
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Rheumatoid
(complications, drug therapy)
- Aspergillosis
(complications, surgery)
- Etanercept
- Humans
- Immunoglobulin G
(therapeutic use)
- Infliximab
- Middle Aged
- Paranasal Sinus Diseases
(complications, surgery)
- Receptors, Tumor Necrosis Factor
(therapeutic use)
- Retrospective Studies
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|